| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Revenues: | ||||||
Grant | ||||||
0 | 3,888 | 5,205 | 4,628 | - | - | |
Grant | ||||||
- | - | - | - | 6,085 | 0 | |
Operating expenses: | ||||||
Research and development | ||||||
64,600 | 36,719 | 22,815 | 18,143 | 11,453 | 6,830 | |
General and administrative | ||||||
15,734 | 12,632 | 10,066 | 8,391 | 5,947 | 2,074 | |
Total operating expenses | ||||||
80,334 | 49,351 | 32,881 | 26,534 | 17,400 | 8,904 | |
Loss from operations | ||||||
-80,334 | -45,463 | -27,676 | -21,906 | -11,315 | -8,904 | |
Other income (expense): | ||||||
Interest income | ||||||
2,143 | 1,172 | 482 | 244 | 22 | 1 | |
Change in fair value of forward sale contract | ||||||
- | - | - | - | - | -1,444 | |
Other expense, net | ||||||
-63 | -57 | -42 | -36 | -2 | - | |
Total other income | ||||||
2,080 | 1,115 | 440 | 208 | 20 | -1,443 | |
Net loss | ||||||
-78,254 | -44,348 | -27,236 | -21,698 | -11,295 | -10,347 | |
Deemed dividend to convertible preferred stockholders | ||||||
- | - | - | - | 228 | - | |
Net loss per share, basic and diluted | ||||||
-2.45 | -2.13 | -1.80 | -2.22 | -19.21 | - | |
Net loss attributable to common stockholders | ||||||
- | - | - | - | -11,523 | -10,347 | |
Weighted-average common shares outstanding, basic and diluted | ||||||
31,949 | 20,822 | 15,128 | 9,791 | 599 | - | |